Two days ago the FDA approved Addyi, a new drug meant to boost the libido in women. While some see this as a victory in achieving parity for women’s health, skeptics see many possible health risks. Robb Report Health & Wellness editor, Janice O’Leary, quizzed Paula Johnson, MD, Brigham & Women’s executive director of the Connors Center for Gender Biology, on the reality of the drug’s efficacy and safety.

Why did Addyi take so long to come to market?

Addyi, or flibanserin, has received a lot of pr…